A Randomized Study of Adjuvant vs NeoAdjuvant Pembrolizumab for Clinically Detectable Stage III-IV High Risk Melanoma (S1801)

A Randomized Study of Adjuvant vs NeoAdjuvant Pembrolizumab for Clinically Detectable Stage III-IV High Risk Melanoma (S1801)

Trial Category:
Melanoma
Phase
II
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members